Tags

Type your tag names separated by a space and hit enter

Crystallization properties in urine from calcium oxalate stone formers.
J Urol. 1995 Sep; 154(3):940-6.JU

Abstract

PURPOSE

We determine whether stone formers and normal subjects can be distinguished in terms of supersaturation with calcium oxalate, and inhibition of calcium oxalate growth and aggregation.

MATERIALS AND METHODS

An estimate of the ion activity product of calcium oxalate was obtained from the analysis of calcium, oxalate, citrate and magnesium in 16-hour urine samples obtained between 6 a.m. and 10 p.m. The inhibition of calcium oxalate crystal growth and aggregation was assessed in 8-hour urine specimens obtained between 10 p.m. and 6 a.m.

RESULTS

The ion activity product of calcium oxalate was higher and inhibition of crystal aggregation was lower in stone formers than in normal subjects. Inhibition of crystal growth was lower only in male stone formers. Quotient 1 (10(2) x ion activity product of calcium oxalate/inhibition of crystal growth), quotient 2 (10(2) x ion activity product of calcium oxalate/inhibition of crystal aggregation) and quotient 3 (10(4) x ion activity product of calcium oxalate/[inhibition of crystal growth x inhibition of crystal aggregation]) were significantly higher in stone formers.

CONCLUSIONS

The biochemical risk situation in calcium oxalate stone formers can be summarized by quotient 2 or 3.

Authors+Show Affiliations

Department of Urology, Faculty of Health Sciences, University Hospital, Linköping, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7637098

Citation

Tiselius, H G., et al. "Crystallization Properties in Urine From Calcium Oxalate Stone Formers." The Journal of Urology, vol. 154, no. 3, 1995, pp. 940-6.
Tiselius HG, Bek-Jensen H, Fornander AM, et al. Crystallization properties in urine from calcium oxalate stone formers. J Urol. 1995;154(3):940-6.
Tiselius, H. G., Bek-Jensen, H., Fornander, A. M., & Nilsson, M. A. (1995). Crystallization properties in urine from calcium oxalate stone formers. The Journal of Urology, 154(3), 940-6.
Tiselius HG, et al. Crystallization Properties in Urine From Calcium Oxalate Stone Formers. J Urol. 1995;154(3):940-6. PubMed PMID: 7637098.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Crystallization properties in urine from calcium oxalate stone formers. AU - Tiselius,H G, AU - Bek-Jensen,H, AU - Fornander,A M, AU - Nilsson,M A, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez SP - 940 EP - 6 JF - The Journal of urology JO - J Urol VL - 154 IS - 3 N2 - PURPOSE: We determine whether stone formers and normal subjects can be distinguished in terms of supersaturation with calcium oxalate, and inhibition of calcium oxalate growth and aggregation. MATERIALS AND METHODS: An estimate of the ion activity product of calcium oxalate was obtained from the analysis of calcium, oxalate, citrate and magnesium in 16-hour urine samples obtained between 6 a.m. and 10 p.m. The inhibition of calcium oxalate crystal growth and aggregation was assessed in 8-hour urine specimens obtained between 10 p.m. and 6 a.m. RESULTS: The ion activity product of calcium oxalate was higher and inhibition of crystal aggregation was lower in stone formers than in normal subjects. Inhibition of crystal growth was lower only in male stone formers. Quotient 1 (10(2) x ion activity product of calcium oxalate/inhibition of crystal growth), quotient 2 (10(2) x ion activity product of calcium oxalate/inhibition of crystal aggregation) and quotient 3 (10(4) x ion activity product of calcium oxalate/[inhibition of crystal growth x inhibition of crystal aggregation]) were significantly higher in stone formers. CONCLUSIONS: The biochemical risk situation in calcium oxalate stone formers can be summarized by quotient 2 or 3. SN - 0022-5347 UR - https://www.unboundmedicine.com/medline/citation/7637098/Crystallization_properties_in_urine_from_calcium_oxalate_stone_formers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-5347(01)66939-8 DB - PRIME DP - Unbound Medicine ER -